SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys

Abstract

Background Population-based data on COVID-19 are essential for guiding policies. There are few such studies, particularly from low or middle-income countries. Brazil is currently a hotspot for COVID-19 globally. We aimed to investigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody prevalence by city and according to sex, age, ethnicity group, and socioeconomic status, and compare seroprevalence estimates with official statistics on deaths and cases. Methods In this repeated cross-sectional study, we did two seroprevalence surveys in 133 sentinel cities in all Brazilian states. We randomly selected households and randomly selected one individual from all household members. We excluded children younger than 1 year. Presence of antibodies against SARS-CoV-2 was assessed using a lateral flow point-of-care test, the WONDFO SARS-CoV-2 Antibody Test (Wondfo Biotech, Guangzhou, China), using two drops of blood from finger prick samples. This lateral-flow assay detects IgG and IgM isotypes that are specific to the SARS-CoV-2 receptor binding domain of the spike protein. Participants also answered short questionnaires on sociodemographic information (sex, age, education, ethnicity, household size, and household assets) and compliance with physical distancing measures. Findings We included 25 025 participants in the first survey (May 14–21) and 31 165 in the second (June 4–7). For the 83 (62%) cities with sample sizes of more than 200 participants in both surveys, the pooled seroprevalence increased from 1·9% (95% CI 1·7–2·1) to 3·1% (2·8–3·4). City-level prevalence ranged from 0% to 25·4% in both surveys. 11 (69%) of 16 cities with prevalence above 2·0% in the first survey were located in a stretch along a 2000 km of the Amazon river in the northern region. In the second survey, we found 34 cities with prevalence above 2·0%, which included the same 11 Amazon cities plus 14 from the northeast region, where prevalence was increasing rapidly. Prevalence levels were lower in the south and centre-west, and intermediate in the southeast, where the highest level was found in Rio de Janeiro (7·5% [4·2–12·2]). In the second survey, prevalence was similar in men and women, but an increased prevalence was observed in participants aged 20–59 years and those living in crowded conditions (4·4% [3·5–5·6] for those living with households with six or more people). Prevalence among Indigenous people was 6·4% (4·1–9·4) compared with 1·4% (1·2–1·7) among White people. Prevalence in the poorest socioeconomic quintile was 3·7% (3·2–4·3) compared with 1·7% (1·4–2·2) in the wealthiest quintile. Interpretation Antibody prevalence was highly heterogeneous by country region, with rapid initial escalation in Brazil's north and northeast. Prevalence is strongly associated with Indigenous ancestry and low socioeconomic status. These population subgroups are unlikely to be protected if the policy response to the pandemic by th...

Mass SARS-CoV-2 serological screening for the Principality of Andorra

“…We observed an overall seroprevalence of 11.0%, higher than other studies conducted at around the same time in neighboring countries. [11][12][13][14][15][16][17][18][19][20] This might be due to the population in ux from areas with high seroprevalence in Spain or France, who travel frequently to Andorra. In a study conducted in the Spanish population, 11 the overall seroprevalence during the rst fortnight of May was 5% (95% CI 4.7-5.4) with marked regional differences; there was a higher seroprevalence in the central area of the country (11.3%), where Madrid is located and in the province of Barcelona (7.0%), the latter closely communicated with Andorra.…”

“…The study included two cross-sectional serological surveys using a rapid serological test on a nger prick blood sample. The rst survey (day 0-10) began on 4 May, 2020, and the second started 2 weeks after the end of the rst one (day [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28]. The objectives of the second survey were two-fold: a) to detect seroconversion in participants who might have been infected at the time of the rst survey, and b) to account for indeterminate results or potential false negative results of the test in the rst survey.…”

“…Most seroprevalence studies performed in other settings have included speci c high-risk groups or randomly-selected participants which exclude certain population groups, such as ill or quarantined people, or institutionalized individuals, among others. [11][12][13][14][15][16][17][18][19][20][21] Thus, their results might not accurately re ect the actual seroprevalence in the population. To date, no studies have been published attempting to estimate SARS-CoV-2 seroprevalence in a country by universal serological testing.…”

The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study

“…While many studies attempt to recruit a representative sample, most do not end up analyzing one. [ [12] , [13] , [14] , [15] , [16] , [17] , [18] ] Those that do involve an extensive effort; two Italian studies tested nearly the entire population of Vo [ 19 ] and Lombardy, [ 20 ] and a nation-wide Spanish study tested over 60,000 residents. [ 21 ] A study in Atlanta, Georgia was able to closely represent the population but had to send staff door-to-door to enroll based on US Census blocks.…”

Representative Estimates of COVID-19 Infection Fatality Rates from Three Locations in India

“…Seroprevalence studies in low-and middle-income countries have given rise to several population-representative estimates of overall IFR (9)(10)(11)(12)(13)(14). Ioannidis (15) additionally estimates IFR in several developing countries by combining population-representative seroprevalence surveys (16)(17)(18), and subpopulation-specific surveys (e.g.…”